Freya Biosciences Reports Positive Phase 1 Results for FB301 in IVF-Related Embryo Implantation Failure
核心洞察
Freya Biosciences (搜索) announced positive Phase 1 results for FB301, a multi-strain Lactobacillus consortium (搜索) targeting IVF-related embryo implantation failure (搜索), demonstrating safety and tolerability across all dosing cohorts with no serious adverse events.
The study showed clinically meaningful microbiome modulation with significant increases in Lactobacillus abundance (p < 0.001) and 50% of participants in the highest dose group converting to non-dysbiotic profiles at 6-month follow-up.
The company has received FDA IND clearance for Phase 2 trials in the US and CTA approval in Germany, advancing development of this potential treatment for millions of women undergoing IVF worldwide.
Freya Biosciences (搜索) has announced positive topline results from its Phase 1 first-in-human clinical study of FB301, a defined multi-strain Lactobacillus consortium (搜索) developed as a potential treatment for IVF-related embryo implantation failure (搜索). The randomized, placebo-controlled, double-blind trial demonstrated that FB301 was safe and well tolerated while achieving clinically meaningful microbiome modulation in healthy female subjects.
Study Design and Safety Profile
The Phase 1 trial enrolled 129 participants, with 89 randomized across three dosing cohorts at a single study site in Germany. Healthy female subjects aged 18-45 received either a single vaginal capsule of FB301 (Cohort 1), once-daily dosing for five days (Cohort 2), or once-daily dosing for ten days (Cohort 3). The study met all primary and secondary endpoints, with no serious adverse events, severe adverse events, or discontinuations reported across all cohorts.
"FB301 showed a favorable safety profile across all dose levels and demonstrated clinically meaningful microbiome changes, including increases in key Lactobacillus species in the vaginal environment that are associated with superior health outcomes," said Colleen Acosta, Chief Executive Officer of Freya Biosciences (搜索).
Microbiome Modulation Results
Treatment with FB301 resulted in significant increases in the relative abundance of selected Lactobacillus species in vaginal samples, indicating modulation toward a more advantageous microbiome state. In participants who were dysbiotic at baseline, FB301 treatment led to conversion to a Lactobacillus-dominant microbiome profile across all dosing cohorts.
The most compelling results emerged from the 6-month follow-up data, where 50.0% (11/22) of participants in the highest dose group (Cohort 3) had converted to a non-dysbiotic profile, compared with only 11.1% (1/9) in the placebo group. Statistical analyses confirmed significant increases in Lactobacillus abundance versus baseline across treatment arms (p < 0.001), with additional pooled analyses supporting treatment effects compared to placebo.
Platform Validation and Mechanism
Johan van Hylckama Vlieg, Chief Scientific Officer of Freya Biosciences (搜索), noted that FB301 met the secondary endpoint of improving Lactobacillus abundance compared to placebo without requiring antibiotic pretreatment. The study demonstrated durable engraftment of FB301 product strains, validating Freya's Dyscover™ platform for discovering therapeutic candidates that correct local immune dysregulation.
FB301 was developed using Freya's Dyscover™ platform, a multi-omics data science platform built on a biobank of over 1,000 patient samples. The proposed mechanism of action involves resolving dysbiotic vaginal microbiome (搜索) conditions and addressing underlying inflammation, which are critical factors in reproductive health.
Phase 2 Development Plans
Based on these positive results, Freya is advancing FB301 into Phase 2 clinical development to evaluate its potential in women undergoing assisted reproductive technologies, including frozen embryo transfer, as well as in bacterial vaginosis (搜索) populations to optimize treatment regimens. The FDA has cleared an Investigational New Drug application for a US study in women undergoing frozen embryo transfer (NCT07453069), and Germany has approved a Clinical Trial Application for a bacterial vaginosis treatment optimization study (NCT07481955).
Acosta emphasized the clinical significance of these developments: "As we advance into Phase 2, our focus will be on confirming these findings in patient populations and progressing the development of a much-needed new therapeutic option that could help improve outcomes for the millions of women undergoing IVF worldwide."
Company Background
Freya Biosciences (搜索) is a clinical-stage immunology company developing therapies for inflammation and immune dysregulation in women's health conditions. The company is advancing a diversified pipeline that includes two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure (搜索) and preterm birth (搜索). Freya is supported by an international investor base including Sofinnova Partners (搜索), the Gates Foundation (搜索), OMX Ventures (搜索), EIFO (搜索), and Angelini Ventures (搜索).